Abstract
For more than four decades there has been a search for selective inhibitors of GABA transporters. This has led to potent and selective inhibitors of the cloned GABA transporter subtype GAT1, which is responsible for a majority of neuronal GABA transport. The only clinically approved compound with this mechanism of action is Tiagabine. Other GABA transporter subtypes have not been targeted with comparable selectivity and potency. We here review a comprehensive series of competitive inhibitors that provide information about the GABA recognition site and summarise the structure-activity relations in a ligand-based pharmacophore model that suggests how future compounds could be designed. Finally, some of the recent results on subtype-characterised competitive inhibitors and recent lipophilic aromatic GABA uptake inhibitors are reviewed.
Keywords: Acyclic GABA Analogues, THPO, Nipecotic Acid, Aminocyclohexanecarboxylic Acid (ACHC), GABA uptake assay
Current Topics in Medicinal Chemistry
Title: Structure-Activity Relationships of Selective GABA Uptake Inhibitors
Volume: 6 Issue: 17
Author(s): Signe Hog, Jeremy R. Greenwood, Karsten B. Madsen, Orla M. Larsson, Bente Frolund, Arne Schousboe, Povl Krogsgaard-Larsen and Rasmus P. Clausen
Affiliation:
Keywords: Acyclic GABA Analogues, THPO, Nipecotic Acid, Aminocyclohexanecarboxylic Acid (ACHC), GABA uptake assay
Abstract: For more than four decades there has been a search for selective inhibitors of GABA transporters. This has led to potent and selective inhibitors of the cloned GABA transporter subtype GAT1, which is responsible for a majority of neuronal GABA transport. The only clinically approved compound with this mechanism of action is Tiagabine. Other GABA transporter subtypes have not been targeted with comparable selectivity and potency. We here review a comprehensive series of competitive inhibitors that provide information about the GABA recognition site and summarise the structure-activity relations in a ligand-based pharmacophore model that suggests how future compounds could be designed. Finally, some of the recent results on subtype-characterised competitive inhibitors and recent lipophilic aromatic GABA uptake inhibitors are reviewed.
Export Options
About this article
Cite this article as:
Hog Signe, Greenwood R. Jeremy, Madsen B. Karsten, Larsson M. Orla, Frolund Bente, Schousboe Arne, Krogsgaard-Larsen Povl and Clausen P. Rasmus, Structure-Activity Relationships of Selective GABA Uptake Inhibitors, Current Topics in Medicinal Chemistry 2006; 6 (17) . https://dx.doi.org/10.2174/156802606778249801
DOI https://dx.doi.org/10.2174/156802606778249801 |
Print ISSN 1568-0266 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4294 |
Call for Papers in Thematic Issues
Chemistry Based on Natural Products for Therapeutic Purposes
The development of new pharmaceuticals for a wide range of medical conditions has long relied on the identification of promising natural products (NPs). There are over sixty percent of cancer, infectious illness, and CNS disease medications that include an NP pharmacophore, according to the Food and Drug Administration. Since NP ...read more
Current Trends in Drug Discovery Based on Artificial Intelligence and Computer-Aided Drug Design
Drug development discovery has faced several challenges over the years. In fact, the evolution of classical approaches to modern methods using computational methods, or Computer-Aided Drug Design (CADD), has shown promising and essential results in any drug discovery campaign. Among these methods, molecular docking is one of the most notable ...read more
Drug Discovery in the Age of Artificial Intelligence
In the age of artificial intelligence (AI), we have witnessed a significant boom in AI techniques for drug discovery. AI techniques are increasingly integrated and accelerating the drug discovery process. These developments have not only attracted the attention of academia and industry but also raised important questions regarding the selection ...read more
From Biodiversity to Chemical Diversity: Focus of Flavonoids
Flavonoids are the largest group of polyphenols, plant secondary metabolites arising from the essential aromatic amino acid phenylalanine (or more rarely from tyrosine) via the phenylpropanoid pathway. The flavan nucleus is the basic 15-carbon skeleton of flavonoids (C6-C3-C6), which consists of two phenyl rings (A and B) and a heterocyclic ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
AED Strategy after Refractory Epilepsy Surgery
Current Pharmaceutical Design Self-Regulatory Control and Habit Learning in the Development of Eating Disorders
Current Psychiatry Reviews Preface [Hot topic: Carbohydrates (Executive Editor: Istvan Toth)]
Mini-Reviews in Medicinal Chemistry Understanding Membrane Protein Drug Targets in Computational Perspective
Current Drug Targets Medical Management and Risk Reduction of the Cardiovascular Effects of Underwater Diving
Current Vascular Pharmacology The Structural Features of α-Conotoxin Specifically Target Different Isoforms of Nicotinic Acetylcholine Receptors
Current Topics in Medicinal Chemistry Quality of Life of Children with Cerebral Palsy: A Cross-Sectional KIDSCREEN study in the Southern part of the Netherlands
CNS & Neurological Disorders - Drug Targets Polypharmacological Properties and Therapeutic Potential of β-Caryophyllene: A Dietary Phytocannabinoid of Pharmaceutical Promise
Current Pharmaceutical Design Schizophrenia and the Neglect Syndrome: Parietal Contributions to Cognitive Dysfunction in Schizophrenia
Current Psychiatry Reviews Neuroimaging of Cancer Patients for Psychosocial Support and Patient Care
Current Medical Imaging Nimodipine Reappraised: An Old Drug With a Future
Current Neuropharmacology Pharmacological Management of Huntingtons Disease: An Evidence- Based Review
Current Pharmaceutical Design ATP-Binding Cassette Efflux Transporters in Human Placenta
Current Pharmaceutical Biotechnology The Interaction of Zinc Oxide/Green Tea Extract Complex Nanoparticles and its Effect on Monosodium Glutamate Toxicity in Liver of Rats
Current Pharmaceutical Biotechnology Mitochondrial Dysfunction and Its Relationship with mTOR Signaling and Oxidative Damage in Autism Spectrum Disorders
Mini-Reviews in Medicinal Chemistry Recent Advances in Medicinal Chemistry and Pharmaceutical Technology- Strategies for Drug Delivery to the Brain
Current Topics in Medicinal Chemistry Endoplasmic Reticulum Protein Quality Control in Neurodegenerative Disease: The Good, the Bad and the Therapy
Current Medicinal Chemistry NAP (Davunetide) Provides Functional and Structural Neuroprotection
Current Pharmaceutical Design University of Kentucky Sanders-Brown Healthy Brain Aging Volunteers: Donor Characteristics, Procedures and Neuropathology
Current Alzheimer Research Nicotinic Acetylcholine Receptors and Epilepsy
Current Drug Targets - CNS & Neurological Disorders